Vermont’s attorney general’s office announced Thursday that it will continue its lawsuit against Purdue Pharma for the company’s alleged role in fueling opioid addiction in the Green Mountain State, after a state judge ruled against the OxyContin maker’s bid to kill the case.
Ares Life Sciences said Thursday it will snap up the rest of French allergy pharmaceutical company Stallergenes Greer it doesn’t already own in a 730.1 million euro ($832.5 million) deal guided by Skadden and Clifford Chance.
A Kentucky federal court granted preliminary approval on Thursday to a settlement in which Omnicare Inc. agreed to pay $20 million to resolve a 13-year-old securities suit that at one point made its way to the U.S. Supreme Court.
A New Jersey federal judge told a pension fund on Wednesday that it only has standing to pursue securities claims against Dr. Reddy's for five alleged misstatements it made immediately prior to the fund's purchase of the pharmaceutical company's stock.
Career scientist and physician Dr. Norman Sharpless will leave his post as the head of the National Cancer Institute to take over the U.S. Food and Drug Administration when Scott Gottlieb steps down in April. Here’s what you should know about the new interim commissioner.
Sens. Chuck Grassley, R-Iowa, and Ron Wyden, D-Ore., have sent a letter to agencies within the U.S. Department of Health and Human Services seeking answers on their efforts to monitor medical suppliers that are partly owned by the physicians whose practices they supply.
Allergan PLC said a group that claims the company's anti-competitive methods caused it to overpay for its ulcerative colitis drug should not get a second chance at class certification after the First Circuit knocked down its first attempt.
A Johnson & Johnson unit on Thursday urged the Third Circuit to toss a would-be employee's proposed class claims that he was unfairly denied a job due to an erroneous criminal background check, arguing that his agreement to arbitrate claims with a temporary employment staffing agency extended to the pharmaceutical company.
Citing alleged misstatements made by an investor represented by rival attorneys, Block & Leviton LLP and Kaufman Coren & Ress LLP have urged a Pennsylvania federal judge to name them class counsel in litigation accusing Trevena Inc. of artificially inflating its share value.
Law360 is pleased to announce the formation of its 2019 Life Sciences Editorial Advisory Board.
Enforcing intellectual property rights in health care and ensuring competition to everyone’s benefit — especially finding ways to control skyrocketing prescription drug costs — has emerged as a priority at the Federal Trade Commission, a Republican member of the body said Wednesday.
Figuring out what constitutes a manageable workload for the nation’s district judges is no simple task. Getting the judiciary the resources it needs is even harder.
The Western District of Louisiana is supposed to have seven district judges. But for a year, most of the courthouses were operating without a single Article III judge. As usual, magistrate judges picked up the slack.
The full Federal Circuit shot down Zimmer Inc.’s request to re-evaluate the $254 million bill it's facing for infringing Stryker Corp.’s surgical tool patents in a case that led the U.S. Supreme Court to relax the standard for awarding enhanced damages.
An extended time limit for False Claims Act cases where the government doesn't intervene, seemingly supported by the justices at arguments for a pending U.S. Supreme Court case, marks a significant potential expansion of already-high FCA-related risks and costs for federal contractors, attorneys said.
A New York federal judge said that Teva Pharmaceuticals made a "strategic decision" not to challenge expert testimony in a False Claims Act case and that she has "no interest" in revisiting a recent ruling in light of new challenges.
The former owners of bankrupt Johnson & Johnson talc supplier Imerys Talc America Inc. asked a Delaware bankruptcy judge Wednesday to extend to them the protections of the automatic stay granted to the debtor in Chapter 11 cases so a dispute over insurance policy proceeds can be resolved.
Monsanto should pay a California man for failing to warn about its weedkiller Roundup's cancer risks, his attorney told a federal jury during opening statements in the trial's second phase, declining to put a number on punitive damages but noting that Bayer recently acquired Monsanto for $63 billion.
Laboratories that conduct drug tests for employers have a legal duty to the workers they test to perform them accurately, the South Carolina Supreme Court held Wednesday, saying a former BMW employee who was fired for failing a drug screening can sue the lab that tested him over a purported false positive.
A proposed class of Patterson Cos. Inc. investors has asked a Minnesota federal judge not to toss their suit accusing the dental supply company of working with competitors to fix dental supply prices, saying a Federal Trade Commission investigation gave them enough evidence to back up the case's claims.
The U.S. Supreme Court's unanimous ruling on Wednesday in Obduskey v. McCarthy & Holthus LLP removes nearly all activities taken by creditors seeking nonjudicial foreclosure of liens and mortgages from the ambit of the Fair Debt Collection Practices Act, says John Baxter of Nelson Mullins Riley & Scarborough LLP.
Trial counsel’s contribution to the virtual law team throughout the life cycle of a mass tort litigation rests in the key skill of viewing the case through the eyes of the ultimate audience for the defense, the jury, say attorneys at Covington & Burling LLP and Faegre Baker Daniels LLP.
These days, a popular theme in media is that lawyers' jobs will be taken by robots. However, based on the tech issues discussed at the South by Southwest technology conference in Austin, Texas, last month, robots may in fact need lawyers, says Nick Abrahams of Norton Rose Fulbright.
You passed the bar exam and are ready for the character and fitness committee interview. Time to think about how to discuss that minor incident in college, that misdemeanor in high school or that mental health issue that you have totally under control, says Richard Maltz of Frankfurt Kurnit Klein & Selz PC.
In recent years, the U.S. Department of Justice has shown some reluctance to bring cases involving off-label promotion of pharmaceutical products, but this type of marketing remains the driving force behind many product liability and mass tort litigations, say Dae Lee and Jesse Dresser of Frier Levitt LLC.
The U.S. Supreme Court's recent opinion in Nutraceutical v. Lambert held that Federal Rule of Civil Procedure 23(f)’s 14-day limit for class certification appeals is not subject to equitable tolling, presenting important lessons for both the winners and losers of class certification orders, say attorneys at Faegre Baker Daniels.
My initial reaction to "Doing Justice" was that author Preet Bharara may have bitten off more than he could chew — an accusation leveled against him when he served as U.S. attorney for the Southern District of New York — but I found the book full of helpful gems, says U.S. District Judge Cynthia Bashant of the Southern District of California.
Private plaintiffs seeking to bolster their price-fixing complaints by citing government investigations or guilty pleas concerning different markets should consider instructive decisions from the Auto Parts, Generic Drugs, and SRAM and Flash Memory litigations, say William Reiss and Dave Rochelson of Robins Kaplan LLP.
Though most experts believe that an imminent recession is unlikely, slowdown fears are increasing. Now is the time for firms to consider how to best leverage their communications and marketing teams to lessen impacts from a potential economic slowdown, says Tom Orewyler of Tom Orewyler Communications LLC.
Hikma's recent certiorari petition claims the Federal Circuit’s decision in Vanda v. West-Ward amounts to a free pass under Section 101 for method-of-treatment claims. But Vanda is a fact-specific ruling that attempts to find some middle ground in the U.S. Supreme Court’s Section 101 precedents, say Sasha Rao and Erin Gaddes of Maynard Cooper & Gale PC.